Xtant Medical Hldgs Q2 2024 GAAP EPS $(0.03) Misses $(0.02) Estimate, Sales $29.943M Beat $28.700M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xtant Medical Holdings reported its Q2 2024 financial results with a GAAP EPS of $(0.03), missing the estimate of $(0.02). However, the company reported sales of $29.943 million, beating the estimate of $28.700 million.
August 08, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Xtant Medical Holdings reported mixed Q2 2024 results with a GAAP EPS of $(0.03), missing the $(0.02) estimate, but sales of $29.943 million beat the $28.700 million estimate.
The mixed earnings report, with a miss on EPS but a beat on sales, is likely to result in a neutral short-term impact on XTNT's stock price. Investors may weigh the negative EPS against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100